

Table 1. Characteristics of the Patients at Baseline.*

Characteristic	AstraZeneca Trial (N=11,693)		GlaxoSmithKline Trial (N=11,750)		Merck Trial (N=11,744)		Novartis Trial (N=823) [†]		Combined Analysis (N=36,010)	
	ICS (N=5847)	ICS+LABA (N=5846)	ICS (N=5876)	ICS+LABA (N=5874)	ICS (N=5872)	ICS+LABA (N=5872)	ICS (N=411)	ICS+LABA (N=412)	ICS (N=18,006)	ICS+LABA (N=18,004)
	<i>number of patients (percent)</i>									
Age — yr										
12–17	636 (11)	632 (11)	618 (11)	617 (11)	545 (9)	490 (8)	33 (8)	37 (9)	1,832 (10)	1,776 (10)
18–64	4568 (78)	4572 (78)	4632 (79)	4608 (78)	4527 (77)	4579 (78)	320 (78)	328 (80)	14,047 (78)	14,087 (78)
65–91	643 (11)	642 (11)	626 (11)	649 (11)	799 (14)	801 (14)	58 (14)	47 (11)	2,126 (12)	2,139 (12)
Missing data	0	0	0	0	1 (<1)	2 (<1)	0	0	1 (<1)	2 (<1)

各社の年齢構成です。Combinedとは統合した結果です。

Table 2. Asthma-Related Deaths and Other Outcomes (Intention-to-Treat Population).^a					
Variable	AstraZeneca Trial	GlaxoSmithKline Trial	Merck Trial	Novartis Trial	Combined Analysis
Asthma-related death					
In ICS group— no./total no.	0/5847	0/5876	0/5872	0/411	0/18,006
In ICS+LABA group— no./total no.	2/5846	0/5874	0/5872	0/412	2/18,004
Asthma-related intubation					
In ICS group— no./total no.	0/5847	2/5876	0/5872	0/411	2/18,006
In ICS+LABA group— no./total no.	1/5846	0/5874	0/5872	0/412	1/18,004
Asthma-related hospitalization					
In ICS group— no./total no. (%)	40/5847 (0.68)	33/5876 (0.56)	32/5872 (0.54)	3/411 (0.73)	108/18,006 (0.60)
In ICS+LABA group— no./total no. (%)	42/5846 (0.72)	34/5874 (0.58)	39/5872 (0.66)	3/412 (0.73)	118/18,004 (0.66)
Relative risk (95% CI) for ICS+LABA vs. ICS	1.04 (0.66–1.64)	1.02 (0.61–1.69)	1.20 (0.73–1.98)	1.02 (0.14–7.62)	1.08 (0.82–1.41)
P value for between-group difference	0.91	>0.99	0.48	0.99	0.60
P value for interaction	NA	NA	NA	NA	0.96
Serious asthma-related event					
In ICS group— no./total no. (%)	40/5847 (0.68)	33/5876 (0.56)	32/5872 (0.54)	3/411 (0.73)	108/18,006 (0.60)
In ICS+LABA group— no./total no. (%)	43/5846 (0.74)	34/5874 (0.58)	39/5872 (0.66)	3/412 (0.73)	119/18,004 (0.66)
Relative risk (95% CI) in ICS+LABA group vs. ICS group	1.06 (0.67–1.68)	1.02 (0.61–1.69)	1.20 (0.73–1.98)	1.02 (0.14–7.62)	1.09 (0.83–1.43)
P value for between-group difference	0.83	>0.99	0.48	>0.99	0.55
P value for interaction	NA	NA	NA	NA	0.96
Asthma exacerbation					
In ICS group— no./total no. (%)	636/5847 (10.9)	624/5876 (10.6)	779/5872 (13.3)	61/411 (14.8)	2100/18,006 (11.7)
In ICS+LABA group— no./total no. (%)	539/5846 (9.2)	497/5874 (8.5)	688/5872 (11.7)	44/412 (10.7)	1768/18,004 (9.8)
Relative risk (95% CI) for ICS+LABA group vs. ICS group	0.84 (0.75–0.94)	0.79 (0.70–0.89)	0.87 (0.78–0.96)	0.74 (0.49–1.10)	0.83 (0.78–0.89)
P value for between-group difference	0.002	<0.001	0.008	0.14	<0.001
P value for interaction	NA	NA	NA	NA	0.58

* CI denotes confidence interval, ICS inhaled glucocorticoid, LABA long-acting β_2 -agonist, and NA not applicable.